ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1803

Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina

Rodrigo Garcia Salinas1, Maria Alicia Lazaro 2, Santiago Scarafia 3, Alejandra Cusa 2, Nieves Capozzi 4, Luciana Casalla 4, Lucia Zarate 4, Maria de la Vega 5, Maria Correa 6, Gustavo Casado 7, Silvia Papasidero 8, Oscar Rillo 9, Nevil Alejandro Muñoz 10, Mariana Benegas 11, Karin Kirmayr 12, Maria Paula Girard Bosch 13, Maria Victoria Martire 14 and Ramiro Gomez 15, 1Hospital Italiano de La Plata, La plata, Buenos Aires, Argentina, 2IARI, Buenos Aires, 3Hospital Municipal "San Cayetano", Buenos Aires, Buenos Aires, Argentina, 4Hospital Posadas, Buenos Aires, 5CEIM Investigaciones Medicas, Buenos Aires, Argentina, 6Consultorios Reumatológicos Pampa, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 7Hospital Militar Central, Buenos Aires, 8Hospital General de Agudos Dr. E. Tornú, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina, 9Hospital Pirovano, Buenos Aires, 10Hospital Ramos Mejia, Buenos Aires, 11Sanatorio Mendez, Buenos Aires, 12Hospital Zonal Bariloche, Bariloche, 13Instituto Médico Platense, La Plata, 14Hospital San Martín. Instituto Médico Platense, La Plata, 15Hospital de Clínicas José de San Martín, Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: rheumatoid arthritis, treatment and infection

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: 4M090: Infection-Related Rheumatic Disease (1800–1805)

Session Type: ACR Abstract Session

Session Time: 2:30PM-4:00PM

Background/Purpose: The biologics therapies in rheumatoid arthritis (RA) implies a well-known risk of infection. It is of utterly importance to count with predictive models to define risk factors for infection. Objectives: Validate the RABBIT risk score for serious infections in a cohort of RA patients followed for 12 months. Evaluate which variables of our population could be of relevance to optimize the score.

Methods: Patients ≥18 years old fulfilling 2010 ACR/EULAR criteria for RA were included and followed for 12 months. Basal sociodemographic data, comorbidities, RA characteristics and vaccination was consigned . Basal RABBIT score was calculed. Serious infections were consigned, describing site and time since enrollment. Statistical analysis: Categorical variables were compared using x2 test and continual variables using Student´s t test or Mann Whitney. Cumulative survival of infection was assessed using Kaplan Meier curves. Variables associated serious infections were evaluated using Cox proportional regression model.

Results: 605 patients were included. 83.5% female, mean age 52.8±12.8 years, 96.2% urban residence, 83% GRAFFAR III/IV (middle, middle-low class), median years of formal studies 10 (IQR 7-13) years. 70% had health insurance. Median time of RA evolution 84 (36-168) months, 90% RF+, 80% ACPA+, median DAS-28 3.5 (2.4-4.8), median CDAI 10 (3-19) and median HAQ 0.87 (0.37-1.50). Comorbidities: 7% Previous infection, 10% lung disease, 1% chronic kidney disease, 6% diabetes. Vaccination status: 67% antiinfluenza, 66.5% antipneumococcal, 47% antiHBV. Treatment: 75% patients were on MTX. 60% were on csDMARDs alone and 40% on bDMARDs (60% TNFi, 20% Tocilizumab, 13% Abatacept, 7% Tofacitinib). 15.6% had a prior history of bDMARDs use. Mean dose of prednisone was 3.6 mg/day and 75% of patients received under 7.5 mg/day. Incidence of serious infection was 5% (CI95% 3-7). Most frequent sites were respiratory and urinary (90%). Mean time to serious infection was 3.5 mont. Variables associated with serious infection: High disease activity by CDAI 4.1 (1.8-9.5) and DAS-28 3.2 (1.3-7.3), previous serious infection 19.3 (8-47), pulmonary disease 5.2 (2.1-13), diabetes 6.4 (2.3-17.6), prednisone >20mg/day 14.3 (4.8-42.5), Tocilizumab treatment 12.4 (3-53) and current use of DMARDs 0.24 (0.1-0.6). Cox regresión model  (serious infection): Previous serious infection (expB:10.6 p:0.00001), diabetes  (expB:4.8 p:0.02), Tocilizumab treatment (expB: 11.4 p:0.012), high dose of corticoids (expB: 9.3 p:0.008) and current use of DMARDs (expB: 0.3 p:0.04) were independently associated. Performance of RABBIT score: Patients with no infection during follow up had a median score of 1.2 (IQR 0.8-2.1) and patients with infection a median score of 5.1 (IQR 2.15-12.6)(p=0.00001). ROC curve analysis: AUC 0.86 (CI95% 0.8-0.94), best cut-off 2.85 (sensibility 75%,  specificity 85%).

Conclusion: The RABBIT score performed excellently in our patients. Serious infections was 5% during the 12 months, mean time to serious infection was 3.5 months and it was independently associated with previous serious infection, diabetes, use of Tocilizumab, prednisone dose >20 mg/day and negatively with current use of DMARDs.


Disclosure: R. Garcia Salinas, None; M. Lazaro, None; S. Scarafia, None; A. Cusa, None; N. Capozzi, None; L. Casalla, None; L. Zarate, None; M. de la Vega, AbbVie, 8, BMS, 8, Janssen, 8, Lilly, 8, Pfizer, 5, 8, Raffo, 5, 8, Roche, 9, Sanofi, 5, 8; M. Correa, None; G. Casado, None; S. Papasidero, None; O. Rillo, None; N. Muñoz, None; M. Benegas, None; K. Kirmayr, None; M. Girard Bosch, None; M. Martire, None; R. Gomez, None.

To cite this abstract in AMA style:

Garcia Salinas R, Lazaro M, Scarafia S, Cusa A, Capozzi N, Casalla L, Zarate L, de la Vega M, Correa M, Casado G, Papasidero S, Rillo O, Muñoz N, Benegas M, Kirmayr K, Girard Bosch M, Martire M, Gomez R. Performance of the RABBIT Infection Score in a Prospective Multicenter Cohort of Rheumatoid Arthritis Patients from Argentina [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/performance-of-the-rabbit-infection-score-in-a-prospective-multicenter-cohort-of-rheumatoid-arthritis-patients-from-argentina/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/performance-of-the-rabbit-infection-score-in-a-prospective-multicenter-cohort-of-rheumatoid-arthritis-patients-from-argentina/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology